




**GYNECOLOGIC ONCOLOGY GROUP • HEADQUARTERS**

OPERATIONS OFFICE 1234 MARKET STREET • SUITE 430 • PHILADELPHIA, PENNSYLVANIA 19107 • 215-928-6030  
STATISTICAL OFFICE KRESS BUILDING - R.P.M.I. • 666 ELM STREET • BUFFALO, NEW YORK 14263 • 716-845-5702



April 25, 1980


Joshua Lederberg, Ph.D.  
Chairman  
President of Rockefeller University  
New York, New York 10021

Dear Dr. Lederberg:

In January, 1978, I wrote to the National Cancer Advisory Board Members individually, calling to their attention the importance of the area of cooperative clinical investigation for gynecologic cancer. The letter had been written because the Gynecologic Oncology Group had had an unfavorable review by the CCIRC with a resulting split vote relative to disapproval. Dr. Vincent DeVita brought to the attention of the Board the entire situation that pertained to the Gynecologic Oncology Group at that time. I do not need to repeat at this time the information which I transmitted, but I assured the National Cancer Advisory Board that the Gynecologic Oncology Group would definitely do its best to bring itself up to the point where it would receive high ratings as a result of its productive multi-discipline efforts. The Group has indeed accomplished the objectives in meeting the requirements of the CCIRC and the National Cancer Advisory Board.

A financial squeeze has occurred. The Gynecologic Oncology Group has received an excellent rating only to find that there is no financial recognition for its accomplishments in comparison with what other groups have received as they progressed over the years. I am enclosing a copy of a letter I recently sent to Dr. DeVita after his office and the Division of Cancer Treatment very kindly arranged for Dr. John Macdonald to meet with representatives of the Gynecologic Oncology Group on April 17, 1980. The letter with its attached enclosures is being provided to you as a member of the National Cancer Advisory Board to bring you up to date. It is intended to indicate to you that the Gynecologic Oncology Group did fulfill the National Cancer Advisory Board's expectations and it will continue to strive to do so. The letters also intended to indicate the current financial improvement of the Gynecologic Oncology Group, so that the Board may have this bit of evidence in its overall view of the relative priorities of various programs coming under its jurisdiction. It is hoped that Dr. DeVita will be able to resolve satisfactorily the many financial dilemmas that he faces with your help, the support of Congress and many others who are devoted to the treatment and prevention of cancer.

Sincerely yours,

  
George C. Lewis, Jr. M.D.  
Group Chairman

GCL:rk